Authors: BRICKL R HEINZEL G WEISENBERGER H SCHUBERT H RUTSCH W ROTH W

Citation: R. Brickl et al., PK PD SIMULATIONS AS A TOOL FOR RATIONAL DESIGN OF CLINICAL DOSAGE REGIMENS - AN EXAMPLE WITH FRADAFIBAN/, International journal of clinical pharmacology and therapeutics, 35(10), 1997, pp. 475-480

Authors: NARJES H MULLER TH WEISENBERGER H GUTH B BRICKL R

Citation: H. Narjes et al., INHIBITION OF PLATELET-AGGREGATION AS A SURROGATE MARKER, Journal of clinical pharmacology, 37(1), 1997, pp. 59-64

Authors: MULLER TH WEISENBERGER H BRICKL R NARJES H HIMMELSBACH F KRAUSE J

Citation: Th. Muller et al., PROFOUND AND SUSTAINED INHIBITION OF PLATELET-AGGREGATION BY FRADAFIBAN, A NONPEPTIDE PLATELET GLYCOPROTEIN IIB IIIA ANTAGONIST, AND ITS ORALLY-ACTIVE PRODRUG, LEFRADAFIBAN, IN MEN/, Circulation, 96(4), 1997, pp. 1130-1138

Authors: VONNICOLAI H BRICKL R ESCHEY H GREISCHEL A HEINZEL G KONIG E LIMMER J RUPPRECHT E

Citation: H. Vonnicolai et al., DURATION OF ACTION AND PHARMACOKINETICS OF THE ORAL ANTIDIABETIC DRUGGLIQUIDONE IN PATIENTS WITH NON-INSULIN-DEPENDENT (TYPE-2) DIABETES-MELLITUS, Arzneimittel-Forschung, 47(3), 1997, pp. 247-252

Authors: MULLER TH WEISENBERGER H BRICKL R KIRCHNER M NARJES H HIMMELSBACH F GUTH B KRAUSE J

Citation: Th. Muller et al., PHARMACODYNAMICS AND PHARMACOKINETICS OF BIBU-52, A PLATELET GLYCOPROTEIN (GP) IIB IIIA ANTAGONIST, AND ITS ORALLY-ACTIVE PRODRUG BIBU-104 IN MAN/, Thrombosis and haemostasis, 73(6), 1995, pp. 1445-1445

Authors: MULLER TH WEISENBERGER H BRICKL R RUHR K NARJES H HIMMELSBACH F

Citation: Th. Muller et al., ANTI-AGGREGATORY PROFILE OF THE PLATELET GLYCOPROTEIN (GP) IIB IIIA ANTAGONIST BIBU-52 IN EX-VIVO STUDIES IN MAN/, Thrombosis and haemostasis, 73(6), 1995, pp. 1447-1447